PTH and stage 5 chronic kidney disease: However, for the individual patient the optimal PTH target levels is difficult to determine as patients with end-stage renal disease show a high interindividual variability in PTH resistance through different mechanisms[43–45] and both high- and low-turnover bone disease can occur over a broad range of PTH levels[46].